Pfizer (PFE) Other Accumulated Expenses (2009 - 2026)

Pfizer (PFE) has reported Other Accumulated Expenses for 17 consecutive years, with $19.7 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Other Accumulated Expenses rose 6.1% year-over-year to $19.7 billion in Q2 2026; TTM through Jun 2026 was $19.7 billion, a 6.1% increase from a year earlier, with the FY2025 full-year figure at $19.4 billion, down 1.46% from the prior year.
• Other Accumulated Expenses was $19.7 billion for Q2 2026 at Pfizer, down from $20.1 billion in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $24.6 billion in Q2 2022 and troughed at $16.1 billion in Q3 2023.
• A 5-year average of $20.0 billion and a median of $19.8 billion in 2024 frame the typical range for Other Accumulated Expenses.
• Across the five-year window, Other Accumulated Expenses surged 92.08% in 2022 and sank 32.49% in 2023, its largest moves.
• Over 5 years, Other Accumulated Expenses stood at $22.6 billion in 2022, then retreated by 9.0% to $20.5 billion in 2023, then fell by 3.98% to $19.7 billion in 2024, then decreased by 1.46% to $19.4 billion in 2025, then gained by 1.43% to $19.7 billion in 2026.
• The last three Other Accumulated Expenses figures came in at $19.7 billion (Q2 2026), $20.1 billion (Q1 2026), and $19.4 billion (Q4 2025), per Business Quant data.